Angelini Pharma’s $4B Acquisition Adds Rare Disease Drugs to a Global Growth StrategyNews DeskMay 7, 20260 Angelini Pharma is acquiring Catalyst Pharmaceuticals in a $4.1 billion deal that gives the Italy-based brain medicines company three commercialized…